NGM Biopharmaceuticals, Inc.
https://www.ngmbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NGM Biopharmaceuticals, Inc.
OncoResponse Mines PD-1 Therapy “Elite Responders” For IO Breakthroughs
Emerging Company Profile: Harvesting blood and tissue samples from patients treated with PD-1 immunotherapy, OncoResponse is developing antibodies it believes can transform cold solid tumors into hot.
Deal Watch: Pfizer Invests In Spero, Parexel Trades Hands
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
NGM Phase IIb NASH Failure Could Darken Competitors’ Prospects
NGM will not proceed with a Phase III study in F2/F3 NASH following failure to show fibrosis benefit in Phase IIb. Analysts say this setback could portend disappointing readouts for other NASH players.
Akero First To Show Benefit In Cirrhotic NASH Patients
Although the data are from a small cohort of an ongoing study, Akero’s FGF21 analog reduces fibrosis score by at least one stage in 33% of cirrhotic NASH patients.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies